


## GE acquires Amersham for \$9.5 billion ...

13 November 2003 | News



On 10 October 2003, when General Electric Co. and Amersham PLC announced that they have reached an agreement on the terms of an all-stock transaction, a new beginning was unleashed. As per the deal, GE will acquire all the outstanding shares of Amersham at 800 pence and the diluted share capital of Amersham at approximately \$9.5 billion. The announcement is important not only for the size of the deal but beyond that. The more far-reaching outcome of the deal is that GE will have an edge in harnessing the use of genetics in treating patients. The deal puts GE in direct competition with diagnostic and drug firms like Roche and Abbott Laboratories.

Does this buy out really matter? IBM Lifescience's prediction on future of pharma reads as: "In 2010, the pharmaceutical industry (pharma) will not emissiak writing powders it will sell a variety of products and therapeutic healthcare packages that include diagnostic tests, drugs and monitoring devices and mechanisms, as well as a wide range of services to support parties that each hours hake carged Queen solutions", as we call them, will deliver bigger shareholder returns than they have ever delivered before."

My vision for GE Healthcare Technologies is that we are the

llbadstrgtelaagnobsetctioon@Earisytalkinatyviseavoilleföriotreelyeaaneswchapter∥in writing. While GE is a leading manufacturer of the ncaepitessitikeelelositeon EachiesiovilTooteogradealy (Pagricanid MRI scanners, Amersham is the leading player in the market for cionforrasation of the ayes consciultraisos and MR/ayand PET scans. GE's management believes the acquisition will hletociatoemeateea helathbatedayingdayngsiidswiiluhtave oo onloi 2003 pro forma revenues in excess of \$13 billion. Tomorrow's includes genetic understanding both for

The Aspersition to the passe play special 0.2000 ipeople warlowide and had sales of \$2.43 billion in 2002. It has three main businesstatesis medical diagnosticat protein separations and discovery systems. Amersham Health (59 percent of total Agrieusbam പ്രമുട്ടെ പ്രൂഹ്ലിയുട്ടെ സ്ഥാന്ത്ര പ്രാവാധ ക്രാവാരി വിധാന്ത്ര വിധാനം വിധാന് വിധാന് വിധാന് വിധാന് വി ineaging modalities that are used in medical imaging procedures. Protein separations (17 percent of total Amersham sales in ்க்ளு புள்ளை ithe devel என்ன வந்தைய் வாட்கள் பாகர்கள் முற்ற வரிக்கள் வரிக lesearch and drug development Diseavery systems (24 percent of total Amersham sales in 2002) develops, manufactures acinh distribution in the property of the prop applications including protein and bioassays.

he combination of Amersham and GE Medical is expected by GE to be non-dilutive to 2004 earnings per share (before inprocess research and development charges) and \$0.01 accreti∀e in 2005. GE expects to generate revenue synergies by the end of the third full year to the tune of \$350-400 million per annum, which would translate into operating profit synergy benefits of \$100-200 million per annum.

So it's a transformation. It will deliver a better quality of life. It will deliver better cost effectiveness for the health care challenges, the cost challenges, around the world and it is a vision that is almost a reality today. It's following on very quickly from the rapid developments in IT and the rapid understanding of biology that descends from the sequencing of the human genome and the better understanding of proteins in the body. It's the most exciting age in terms of biological science. I have the privilege of, in the future, leading the leading diagnostic company in realising the benefits of high technology for our consumers and customers worldwide.